意大利人口中的Apolipoprotein E和阿尔茨海默氏病:系统审查和元分析
Diana Marisol Abrego-Guandique1, Giorgia Francesca Saraceno2, Roberto Cannataro3,4
1Department of Health Sciences, University of Magna Graecia Catanzaro, 88100 Catanzaro, Italy.
Brain sciences
|September 28, 2024
概括
在意大利人中,APOE ε4等位基因显著增加了阿尔茨海默病的风险,而APOE ε2则提供了保护. 这一元分析强调了影响AD发展和预防策略的遗传因素.
科学领域:
- 遗传学 是一个遗传学.
- 神经科学是一个神经科学.
- 流行病学 流行病学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,具有重要的遗传成分.
- 无脂蛋白E (APOE) 基因,特别是其 ε4 基因基因,是晚期发病的阿尔茨海默病的已知危险因素.
- 了解不同人群中APOE基因型相关的特定风险对于风险评估和有针对性的干预至关重要.
研究的目的:
- 进行系统审查和元分析,评估APOE等位基因型与意大利人口中阿尔茨海默病风险之间的关联.
- 量化不同APOE基因型 (ε2, ε3, ε4) 与AD发病率相关的风险.
- 探索意大利内部协会的区域差异.
主要方法:
- 在Web of Science,PubMed和Scopus数据库中的系统文献搜索,截至2023年11月15日.
- 用固定和随机效应模型计算几率比率 (OR) 和95%置信区间 (CI) 的15项研究的元分析.
- 遵守PRISMA指南和PROSPERO注册 (CRD42023492580) 的要求.
主要成果:
- APOE ε4等位基因显著增加了AD风险 (OR = 3.60,95% CI [2.90-4.47]).
- APOE ε4ε4基因型显示出最高风险 (OR = 7.08,95% CI [4.22-11.86]),而APOE ε2ε4没有显著性 (OR = 1.36,95% CI [0.76-2.41]).
- APOE ε2 (OR = 0.47,95% CI [0.29-0.74]) 和APOE ε3 (OR = 0.49,95% CI [0.37-0.65]) 的等位基因表现出对AD的保护作用. 在意大利北部观察到更高的风险.
结论:
- 在意大利人口中,具有APOE ε4等位基因的个体患阿尔茨海默病的风险要大得多.
- APOE ε2等位基因似乎对阿尔茨海默病具有保护作用.
- 进一步研究复杂的遗传和环境相互作用对于开发有效的AD预防策略至关重要.
更多相关视频
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
7.8K
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
779
相关概念视频
Alzheimer's Disease: Overview
451
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
451
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Amyloid Fibrils
9.3K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.3K
